The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection

Jordan, 2019, Novel therapeutic approaches to allosensitization and antibody-mediated rejection, Transplantation., 103, 262, 10.1097/TP.0000000000002462 Loupy, 2018, Antibody-mediated rejection of solid-organ allografts, N Engl J Med., 379, 1150, 10.1056/NEJMra1802677 Valenzuela, 2017, Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies, J Clin Invest., 127, 2492, 10.1172/JCI90597 Vincenti, 2016, Belatacept and long-term outcomes in kidney transplantation, N Engl J Med., 374, 2600 Chen, 2015, Cutting edge: CTLA-4Ig inhibits memory B cell responses and promotes allograft survival in sensitized recipients, J Immunol., 195, 4069, 10.4049/jimmunol.1500940 Kim, 2016, Immunological characterization of de novo and recall alloantibody suppression by CTLA4Ig in a mouse model of allosensitization, Transpl Immunol., 38, 84, 10.1016/j.trim.2016.08.001 Ville, 2016, Anti-CD28 antibody and belatacept exert differential effects on mechanisms of renal allograft rejection, J Am Soc Nephrol., 27, 3577, 10.1681/ASN.2015070774 Burghuber, 2019, Dual targeting: combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients, Am J Transplant., 19, 724, 10.1111/ajt.15067 Leibler, 2018, Control of humoral response in renal transplantation by belatacept depends on a direct effect on B cells and impaired T follicular helper-B cell crosstalk, J Am Soc Nephrol., 29, 1049, 10.1681/ASN.2017060679 Leibler, 2019, Belatacept in renal transplant recipient with mild immunologic risk factor: a pilot prospective study (BELACOR), Am J Transplant., 19, 894, 10.1111/ajt.15229 de Weers, 2011, Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors, J Immunol., 186, 1840, 10.4049/jimmunol.1003032 Krejcik, 2016, Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma, Blood., 128, 384, 10.1182/blood-2015-12-687749 Casneuf, 2017, Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma, Blood Adv., 1, 2105, 10.1182/bloodadvances.2017006866 van de Donk, 2018, Immunomodulatory effects of CD38-targeting antibodies, Immunol Lett., 199, 16, 10.1016/j.imlet.2018.04.005 Kwun, 2019, Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use, J Am Soc Nephrol., 30, 1206, 10.1681/ASN.2018121254 Feng, 2017, Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma, Clin Cancer Res., 23, 4290, 10.1158/1078-0432.CCR-16-3192 Cooper D. Safety and Preliminary Clinical Activity of REGN5458, an Anti-BCMA x Anti-CD3 Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma, D. Madduri, Editor. 2019, Meeting of American Society of Hematology: Orlando, FL. Shah, 2019, Multi targeted CAR-T cell therapies for B-cell malignancies, Front Oncol., 9, 146, 10.3389/fonc.2019.00146 Cree, 2019, Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial, Lancet., 394, 1352, 10.1016/S0140-6736(19)31817-3 Hunter, 2015, IL-6 as a keystone cytokine in health and disease, Nat Immunol., 16, 448, 10.1038/ni.3153 Liu, 2016, The biology behind interleukin-6 targeted interventions, Curr Opin Rheumatol., 28, 152, 10.1097/BOR.0000000000000255 Chavele, 2015, Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production, J Immunol., 194, 2482, 10.4049/jimmunol.1401190 Tanaka, 2014, The biology and medical implications of interleukin-6, Cancer Immunol Res., 2, 288, 10.1158/2326-6066.CIR-14-0022 Wood, 2012, Regulatory immune cells in transplantation, Nat Rev Immunol., 12, 417, 10.1038/nri3227 Casiraghi, 1997, Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction, Transplantation., 63, 1508, 10.1097/00007890-199705270-00023 Van Oers, 1988, Interleukin 6 (IL-6) in serum and urine of renal transplant recipients, Clin Exp Immunol., 71, 314 Vandenbroecke, 1991, Differential in situ expression of cytokines in renal allograft rejection, Transplantation., 51, 602, 10.1097/00007890-199103000-00012 Sonkar, 2013, Evaluation of serum interleukin 6 and tumour necrosis factor alpha levels, and their association with various non-immunological parameters in renal transplant recipients, Singapore Med J., 54, 511, 10.11622/smedj.2013174 Chung, 2015, Increase of Th17 cell phenotype in kidney transplant recipients with chronic allograft dysfunction, PLoS ONE., 10, e0145258, 10.1371/journal.pone.0145258 Zhang, 2015, Differentially expressed IL-6Rα and GP130 genes in kidney biopsies (Bxs) suggests different roles of IL-6 signaling in antibody (ABMR)- and cell (CMR)-mediated rejection [abstract], Am J Transplant., 15 Choi, 2017, Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients, Am J Transplant., 17, 2381, 10.1111/ajt.14228 Lion, 2016, HLA class II antibody activation of endothelial cells promotes Th17 and disrupts regulatory T lymphocyte expansion, Am J Transplant., 16, 1408, 10.1111/ajt.13644 Lion, 2019, Clazakizumab acts on endothelial cells to limit antibody mediated damage [abstract], Am J Transplant., 19 Ishibashi, 2017, Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade, Oncotarget., 8, 55230, 10.18632/oncotarget.19420 Aoyama, 2016, Non-human primate lung allograft survival is prolonged by il-6 inhibition and ATG treatment possibly through expansion of peripheral regulatory Tcells. [abstract]. American Transplant Congress, Am J Transplant., 16 Chandran, 2018, IL-6 inhibition with tocilizumab to promote tregs and control renal graft inflammation: a prospective randomized controlled trial [abstract], Am J Transplant., 18, 424 Leung, 2018, Immunologic Impact of tocilizumab treatment in kidney transplant recipients with allograft inflammation [abstract], Am J Transplant., 18, 521 Pottebaum, 2020, Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients, Transplant Direct, 6, e543, 10.1097/TXD.0000000000000988 Jordan SC, Ammerman N, Choi J, et al. Interleukin 6: pathogenic potential and therapeutic approaches in autoimmunity and transplant rejection. 2018;1-12. Weinblatt, 2015, Arthritis Rheumatol., 67, 2591, 10.1002/art.39249 Jordan, 2019, Clazakizumab as an agent to reduce donor specific HLA antibodies and improve outcomes in patients with chronic & active antibody-mediated rejection post-kidney transplantation, Am J Transplant., 19, 452 Clazakizumab for chronic and active antibody mediated rejection post-kidney transplant. https://ClinicalTrials.gov/show/NCT03380377. A pilot trial of clazakizumab in late ABMR. https://ClinicalTrials.gov/show/NCT03444103. Interleukin 6 blockade modifying antibody-mediated graft injury and estimated glomerular filtration rate (eGFR) decline (IMAGINE). https://clinicaltrials.gov/ct2/show/NCT03744910. Cippà, 2019, A late B lymphocyte action in dysfunctional tissue repair following kidney injury and transplantation, Nat Commun., 10, 1157, 10.1038/s41467-019-09092-2 Chun, 2017, Complement dependence of murine costimulatory blockade-resistant cellular cardiac allograft rejection, Am J Transplant., 17, 2810, 10.1111/ajt.14328 Horwitz, 2019, Complement and transplantation: from new mechanisms to potential biomarkers and novel treatment strategies, Clin Lab Med., 39, 31, 10.1016/j.cll.2018.10.004 Gill, 2019, Linking innate immunity and chronic antibody-mediated allograft rejection, Curr Opin Organ Transplant., 24, 694, 10.1097/MOT.0000000000000708 Jordan, 2018, A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients, Am J Transplant., 18, 2955, 10.1111/ajt.14767 Huang, 2020, Three-year outcomes of a randomized, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients, Clin J Am Soc Nephrol., 15, 109, 10.2215/CJN.04840419 Vo, 2015, A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients, Transplantation., 99, 299, 10.1097/TP.0000000000000592 Viglietti, 2016, C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study, Am J Transplant., 16, 1596, 10.1111/ajt.13663 Berger, 2019, Update on C1 esterase inhibitor in human solid organ transplantation, Transplantation., 103, 1763, 10.1097/TP.0000000000002717 Montgomery, 2016, Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study, Am J Transplant., 16, 3468, 10.1111/ajt.13871 Efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care for the treatment of refractory antibody mediated rejection (AMR) in adult renal transplant recipients. https://ClinicalTrials.gov/show/NCT03221842. A multicenter study to evaluate the efficacy and safety of Cinryze® for the treatment of acute antibody-mediated rejection in patients with kidney transplant. https://ClinicalTrials.gov/show/NCT02547220. Lanfranco, 2017, Eculizumab for thrombotic microangiopathy associated with antibody-mediated rejection after ABO-incompatible kidney transplantation, Case Rep Transplant., 2017, 3197042 Locke, 2009, The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection, Am J Transplant., 9, 231, 10.1111/j.1600-6143.2008.02451.x Kocak, 2013, Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports, Transplant Proc., 45, 1022, 10.1016/j.transproceed.2013.02.062 Ghirardo, 2014, Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody, Pediatr Transplant., 18, E1, 10.1111/petr.12187 Lefaucheur, 2018, Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment, J Am Soc Nephrol., 29, 620, 10.1681/ASN.2017050589 Böhmig, 2018, Novel approaches to block complement, Transplantation., 102, 1837, 10.1097/TP.0000000000002267 Viglietti, 2018, Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection, Kidney Int., 94, 773, 10.1016/j.kint.2018.03.015 Tan, 2019, Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: a consecutive series of 15 cases, Transplantation., 103, 2397, 10.1097/TP.0000000000002639 Glotz, 2019, Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies, Am J Transplant., 19, 2865, 10.1111/ajt.15397 Sheridan, 2018, Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action, PLoS ONE., 13, e0195909, 10.1371/journal.pone.0195909 Röth, 2018, Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies, Blood Adv., 2, 2176, 10.1182/bloodadvances.2018020644 Jordan, 2020, Implications of Fc neonatal receptor (FcRn) manipulations for transplant immunotherapeutics, Transplantation., 104, 17, 10.1097/TP.0000000000002912 Eskandary, 2018, Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial, Am J Transplant., 18, 916, 10.1111/ajt.14528 Safety tolerability and activity of TNT009 in healthy volunteers and patients with complement mediated disorders. https://ClinicalTrials.gov/show/NCT02502903. Jordan, 2017, IgG endopeptidase in highly sensitized patients undergoing transplantation, N Engl J Med., 377, 442, 10.1056/NEJMoa1612567 von Pawel-Rammingen, 2002, IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G, EMBO J., 21, 1607, 10.1093/emboj/21.7.1607 Tradtrantip, 2013, Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase, Mol Pharmacol., 83, 1268, 10.1124/mol.113.086470 Phase II study, evaluation of safety and efficacy of ides in chronic kidney disease. https://ClinicalTrials.gov/show/NCT02224820. Toyoda, 2017, Impact of desensitization on antiviral immunity in hla-sensitized kidney transplant recipients, J Immunol Res., 2017, 5672523, 10.1155/2017/5672523 Ge S, Chu M, Choi J, et al. Imlifidase inhibits HLA antibody-mediated NK cell activation and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. Transplantation. 2019. https://doi.org/10.1097/TP.0000000000003023 An efficacy and safety study of imlifidase in treatment of antibody-mediated rejection in kidney transplant patients. NCT03897205. Baldwin, 2019, The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals, Am J Transplant., 19, 1881, 10.1111/ajt.15366 Jordan, 2011, Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients, Am J Transplant., 11, 196, 10.1111/j.1600-6143.2010.03400.x Gelfand, 2012, Intravenous immune globulin in autoimmune and inflammatory diseases, N Engl J Med., 367, 2015, 10.1056/NEJMra1009433 Seijsing, 2018, In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor, Sci Rep., 8, 5141, 10.1038/s41598-018-23481-5 Kiessling, 2017, The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study, Sci Transl Med., 9, eaan1208, 10.1126/scitranslmed.aan1208 Bleeker, 2001, Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect, Blood., 98, 3136, 10.1182/blood.V98.10.3136 Li, 2005, Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases, J Clin Invest., 115, 3440, 10.1172/JCI24394 Hansen, 2002, Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor, Thromb Haemost., 88, 898, 10.1055/s-0037-1613331 Moreso, 2018, Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial, Am J Transplant., 18, 927, 10.1111/ajt.14520 Vincenti, 2010, A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study), Am J Transplant., 10, 535, 10.1111/j.1600-6143.2009.03005.x Durrbach, 2010, A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study), Am J Transplant., 10, 547, 10.1111/j.1600-6143.2010.03016.x